Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Quick facts
Phase 1 pipeline
- autologous T cells & cyclophosphamide
- CD30 CAR-T Cells
- Triple-targeted CAR-T Therapy
- U32 CAR-T
- U87 autologous CAR T-cell
- U87 CAR-T
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: